In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer therapies on the OS of patients with mCRPC.
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry / Francini, Edoardo; Gray, Kathryn P; Shaw, Grace K; Evan, Carolyn P; Hamid, Anis A; Perry, Caitlin E; Kantoff, Philip W; Taplin, Mary-Ellen; Sweeney, Christopher J. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - (2019). [10.1038/s41391-018-0121-2]
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
Francini, EdoardoPrimo
;
2019
Abstract
In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer therapies on the OS of patients with mCRPC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
